Common Stocks of US Pharmaceutical Manufacturing Business

INTRODUCTION
On behalf of Pharmaceutical Resource Technology, Inc., we are cordially inviting you to be part of our journey to bring our company publicly listed on Wall St., as a Shareholder. We are currently making the offering to sell our shares for cash, hoping to raise USD150 million to grow the business. There are benefits and risks inherent in the offering that prospective shareholders are advised to evaluate carefully before investing their money.

Pharmaceutical Resources Technology Inc., is a private corporation, formed in Wyoming, USA in March 2023 with the objectives of consolidating the resources in the pharmaceutical industries to create a product or ranges of products under brand names owned by the clients as though they are the OEM, Original Equipment Manufacturer. The strategy behind is to drive down cost through economy of scales for companies who do not own complex and expensive machineries for the production processes. More value can thus be added to the product itself instead of maintaining the machineries.

Our business is committed to the ongoing education about the use of complementary and quasi medicines to ensure their consistency, effectiveness and safe usage. We make the long and complex supply chain of the pharmaceutical product short by not subjecting our clients to the expensive and time consuming processes like material testing and clinical trial in between the research and development. We use materials and ingredients that are already tested and proven to be safe, effective and consistent. We have completed our product development and production phase and our products are now available for sale.

IF WE ARE ABLE TO GATHER 400 SHAREHOLDERS IN THIS OFFERINGS, WE WILL FILE FOR PUBLIC LISTING IMMEDIATELY.

OUR BUSINESS WILL GROW AS PROJECTED IF WE ARE ABLE TO RAISE THE CAPITALS
CAPITAL RAISED 100% 50% 25%

REVENUE YEAR 1 11M 6M 2M
EBITA YEAR 1 5M 2.5M 0.9M

REVENUE YEAR 2 55M 12M 5M
EBITA YEAR 2 25M 5.4M 2.3M

REVENUE YEAR 3 125M 20M 8M
EBITA YEAR 3 56M 9M 3.6M

ABOUT THE OFFERING
Prior to this Offering, no public market has existed for the common stock of Pharmaceutical Resource Technology, Inc. Upon completion of this Offering, we will attempt to have the shares quoted on the OTC Markets Group, Inc. There is no assurance that the Shares will ever be quoted on the OTC. To be quoted on the OTC, a market maker must apply to make a market in our common stock. As of the date of this offering, we have not made any arrangement with any market makers to quote our shares. In this private offering, we, “Pharmaceutical Resource Technology, Inc", are offering 300,000,000 shares of our common stock. The offering is being made on a self-underwritten, “best efforts” basis. The minimum number of shares required to be purchased by each investor is 2,000. The shares offered by the Company will be sold on a self-underwriter of this offering. We will not receive any commissions or proceeds for selling the shares on our behalf. All of the shares being offered for sale by the Company will be sold at a fixed price of US$0.50 per share for the duration of the Offering. Assuming all of the 300,000,000 shares being offered by the Company are sold, the Company will receive US$150,000,000 in net proceeds. Assuming 150,000,000 shares (50%) being offered by the Company are sold, the Company will receive US$75,000,000 in net proceeds. There is no minimum amount we are required to raise from the shares being offered by the company, and any funds received will be immediately available to us. There is no guarantee that we will sell any of the shares being offered in this offering. Additionally, there is no guarantee that this Offering will successfully raise enough funds to institute our Company's business operation and expansion plan. Additionally, there is no guarantee that a public market will ever develop and you may be unable to sell your shares. This private offering will terminate upon the earliest of

(i) such time when all of the common stock offered has been sold or

(ii) 365 days from the effective date of this prospectus, unless extended by our Board of Directors for an additional 90 days.

We may, however, at any time and for any reason terminate the offering. The proceeds from the sale of the shares sold on behalf of the Company will be placed directly into the Company’s account; any investor who purchases shares will have no assurance that any money aside from their own will be subscribed to the offering. All proceeds from the sale of the shares are non-refundable, except as may be required by applicable laws.

We have not authorized any person to provide you with any information about this Offering, the Company, or the shares of our Common Stock offered hereby that is different from the information included in this offer. If anyone provides you with different information, you should not rely on it.

PROCEDURES FOR SUBSCRIBING (SHARES OFFERED BY US, “THE COMPANY”)
If you decide to subscribe for any shares in this offering that are offered by us, “The Company”, you must download the Shares Subscription Agreement at https://pharmaceuticalresource.com/page.php?n=Download+Prospectus&sid=B532C536U534

- Execute and deliver a subscription agreement; and
- Deliver a check or certified funds to us for acceptance or rejection.

All cheques for subscriptions must be either made payable to “Pharmaceutical Resource Technology, Inc”, Wire transfer and telegraphic transfer are also accepted. The Company will deliver stock certificates attributable to shares of common stock purchased directly to the purchasers within ninety (90) days of the close of the offering. Wire transfer and telegraphic transfer are also accepted. Name of Bank: DBS Bank Ltd, Address: 12 Marina Bay Financial Centre Tower3, Singapore 018982. Swift: DBSSSGSG. Beneficiary: Pharmaceutical Resource Technology, Inc. Account Number: 017-906056-7.

Right to Reject Subscriptions (Shares offered by us, “The Company”)

We have the right to accept or reject subscriptions in whole or in part, for any reason or for no reason. All monies from rejected subscriptions will be returned immediately by us to the subscriber, without interest or deductions. Subscriptions for securities will be accepted or rejected with letter by mail within 48 hours after we receive them. Once the subscriptions for securities is accepted, a share certificated will be issued to the shareholder within the next 7 business day.